Abstract
Drug-eluting stents (DESs) have become the first-line treatment for symptomatic peripheral arterial disease (PAD). Currently, there are many types of DESs on the market. The same type of DESs has different concentrations, and various drugs in them show uneven efficacy. The selection of DESs remains controversial. This study was aimed at comparing the long-term real-world outcomes of different DESs in the treatment of peripheral arterial occlusive disease (PAOD). The databases including Cochrane Library, Embase, and PubMed were searched with a time frame until March 25, 2023. The primary patency (PP) and target lesion revascularization (TLR) at 6 months were used as the primary endpoints. A total of 32 studies (5467 patients) were eligible. At the six-month follow-up, DES-Evero 1 ug/mm2 ranked first in terms of PP, with a significant difference from BMSs (RR [95% CI] = 1.6). DES-Siro 0.9 ug/mm2, DES-Siro 1.4 ug/mm2, DES-Siro 1.95 ug/mm2, DES-PTX 0.167 ug/mm2, DES-PTX 1 ug/mm2 and covered stents (CSs) showed significantly better PPs than BMSs. In terms of TLR, DES-Siro 0.9 ug/mm2 (0.31) ranked first, and DES-Evero 1 ug/mm2 ranked last. Among the treatment modalities for PAD, different DESs showed overall encouraging results in improving PP and TLR compared with BMSs. DES-Evero 1 ug/mm2 showed the best PP, but it had the highest reintervention rate at 6 months. Sirolimus-eluting stents were not always more effective with higher concentrations of sirolimus. Among various DESs, sirolimus-eluting stents and everolimus-eluting stents were superior to paclitaxel-eluting stents.
Similar content being viewed by others
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T et al (2018) 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic Disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)the Task Force for the diagnosis and treatment of peripheral arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 39(9):763–816
Song P, Rudan D, Wang M, Chang X, Rudan I (2019) National and subnational estimation of the prevalence of peripheral artery Disease (PAD) in China: a systematic review and meta-analysis. J Glob Health 9(1):010601
Parikh RB, Victor V, Levy MS (2021) Catheter based interventions for lower extremity peripheral artery Disease. Prog Cardiovasc Dis 69:62–72
Gerhard-Herman M, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE et al (2017) 2016 AHA/ACC Guideline on the management of patients with Lower Extremity Peripheral Artery Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines. Circulation 135(12):e686–e725
Abdullah K, Bou Dargham B, Steinbrecher M, Sun B, Huiqiang Z, Khalili H et al (2018) Drug-eluting stents for treatment of Peripheral Artery Disease. Am J Cardiovasc Drugs 18(3):175–180
Romiti M, Albers M, Brochado-Neto FC, Durazzo A, Pereira C, Luccia ND (2008) Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg 47(5):975–981
Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC et al (2009) Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol 20(9):1141–1150
Bosiers M, Scheinert D, Peeters P, Torsello G, Zeller T, Deloose K et al (2012) Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive Disease. J Vasc Surg 55(2):390–398
Truijers M, Reijnen MMPJ (2015) Commentary: treatment of in-stent restenosis in the superficial femoral artery: at the crossroads of using either covered stents or paclitaxel-based modalities. J Endovasc Ther 22(1):11–13
Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. Eur J Vasc Endovasc Surg 58(1s):S1–S109e33
Taneva GT, Pitoulias GA, Abu Bakr N, Kazemtash M, Muñoz Castellanos J, Donas KP (2022) Assessment of Sirolimus- vs. paCLitaxEl-coated balloon angioPlasty in atherosclerotic femoropopliteal lesiOnS (ASCLEPIOS Study): preliminary results. J Cardiovasc Surg (Torino) 63(1):8–12
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71
Duda SH, Pusich B, Richter G, Landwehr P, Oliva VL, Tielbeek A et al (2002) Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery Disease: six-month results. Circulation 106(12):1505–1509
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Tielbeek A et al (2005) Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery Disease: the SIROCCO II trial. J Vasc Interv Radiol 16(3):331–338
Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tsolakis J (2005) Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-Month angiographic results from a nonrandomized prospective single-center study. J Endovas Ther 12(6):685–695
Falkowski A, Poncyljusz W, Wilk G, Szczerbo-Trojanowska M (2009) The evaluation of primary stenting of sirolimus-eluting versus bare-metal stents in the treatment of atherosclerotic lesions of crural arteries. Eur Radiol 19(4):966–974
Rastan A, Tepe G, Krankenberg H, Zahorsky R, Beschorner U, Noory E et al (2011) Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. EUR HEART J 32(18):2274–2281
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al (2013) Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 61(24):2417–2427
Spreen MI, Martens JM, Hansen BE, Knippenberg B, Verhey E, van Dijk LC et al (2016) Percutaneous transluminal angioplasty and drug-eluting stents for Infrapopliteal Lesions in critical limb ischemia (PADI) trial. Circ Cardiovasc Interv 9(2):e002376
Mori S, Hirano K, Yamauchi Y, Hayashi E, Doijiri T, Takamura T et al (2017) Penetration rate of the placement of a drug-eluting stent for the treatment of superficial femoral artery lesions in Japan. Heart Vessels 32(9):1093–1098
Vent PA, Kaladji A, Davaine JM, Guyomarch B, Chaillou P, Costargent A et al (2017) Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis. Ann Vasc Surg 43:166–75
Björkman P, Auvinen T, Hakovirta H, Romsi P, Turtiainen J, Manninen H et al (2018) Drug-Eluting Stent Shows Similar Patency Results as Prosthetic Bypass in Patients with Femoropopliteal Occlusion in a Randomized Trial. Ann Vasc Surg 53:165–170
Miura T, Miyashita Y, Soga Y, Hozawa K, Doijiri T, Ikeda U et al (2018) Drug-eluting Versus Bare-Metal Stent Implantation with or without Cilostazol in the treatment of the superficial femoral artery. Circ Cardiovasc Interv 11(8):e006564
Kibrik P, Victory J, Patel R, Chait J, Alsheekh A, Aurshina A et al (2019) A real-world experience of drug eluting and non-drug eluting stents in lower extremity peripheral arterial Disease. Vascular 27(6):648–652
Falkowski A, Bogacki H, Szemitko M (2020) Assessment of Mortality and factors affecting outcome of Use of Paclitaxel-Coated stents and Bare Metal stents in Femoropopliteal PAD. J Clin Med 9(7):2221
Iida O, Fujihara M, Kawasaki D, Mori S, Yokoi H, Miyamoto A et al (2021) 24-Month Efficacy and Safety results from Japanese patients in the IMPERIAL Randomized Study of the Eluvia Drug-Eluting Stent and the Zilver PTX Drug-Coated Stent. Cardiovasc Intervent Radiol 44(9):1367–1374
Müller-Hülsbeck S, Benko A, Soga Y, Fujihara M, Iida O, Babaev A et al (2021) Two-year efficacy and safety results from the IMPERIAL Randomized Study of the Eluvia polymer-coated drug-eluting stent and the Zilver PTX polymer-free drug-coated stent. Cardiovasc Intervent Radiol 44(3):368–375
Marples R, Binks M, Spina R, Wright M, Huilgol R (2022) Prophylactic paclitaxel-eluting stent placement does not improve covered femoropopliteal stent patency. Surg Open Science 7:18–21
Tomoi Y, Soga Y, Iida O, Shiraki T, Kobayashi Y, Hiramori S et al (2016) Impact of drug-eluting stent implantation for Femoropopliteal In-Stent occlusion. J Endovasc Ther 23(3):461–467
Ansel GM, Jaff MR, Popma JJ, Battisti AJ, Lottes AE, Harnish P et al (2017) A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal stents in symptomatic patients with Femoropopliteal Disease. J Endovasc Ther 24(4):499–503
Spreen MI, Martens JM, Knippenberg B, van Dijk LC, de Vries JPM, Vos JA et al (2017) Long-term follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting stents for Infrapopliteal Lesions in critical limb ischemia. J Am Heart Assoc 6(4):e004877
Gray WA, Keirse K, Soga Y, Benko A, Babaev A, Yokoi Y et al (2018) A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet 392(10157):1541–1551
Meng FC, Chen PL, Lee CY, Shih CC, Chen IM (2018) Real-world comparison of drug-eluting and Bare-Metal stents in superficial femoral artery Occlusive Disease with Trans-Atlantic Intersociety Consensus B lesions: a 2-Year, single-Institute study. Acta Cardiol Sin 34(2):130–136
Haine A, Schmid MJ, Schindewolf M, Lenz A, Bernhard SM, Drexel H et al (2019) Comparison between interwoven Nitinol and Drug Eluting stents for Endovascular Treatment of Femoropopliteal Artery Disease. Eur J Vasc Endovasc Surg 58(6):865–873
Saratzis A, Rudarakanchana N, Patel S, Diamantopoulos A, Lea T, Corbo B et al (2019) Interwoven Nitinol stents versus Drug Eluting stents in the Femoro-Popliteal segment: a propensity matched analysis. Eur J Vasc Endovasc Surg 58(5):719–727
Gouëffic Y, Sauguet A, Desgranges P, Feugier P, Rosset E, Ducasse E et al (2020) A polymer-free paclitaxel-eluting Stent Versus a Bare-Metal Stent for De Novo Femoropopliteal lesions: the BATTLE trial. JACC Cardiovasc Interv 13(4):447–457
Soga Y, Fujihara M, Iida O, Kawasaki D, Hirano K, Yokoi H et al (2020) Japanese patients treated in the IMPERIAL Randomized Trial comparing Eluvia and Zilver PTX stents. Cardiovasc Intervent Radiol 43(2):215–222
Tsujimura T, Ishihara T, Iida O, Hata Y, Kurata N, Asai M et al (2020) Angioscopic assessments at 3 months after Fluoropolymer-based paclitaxel-eluting stent implantation for Femoropopliteal Endovascular intervention. Circ J 84(11):1999–2005
Zamani N, Sharath SE, Browder RC, Barshes NR, Braun JD, Mills JL Sr et al (2021) Outcomes after Endovascular Stent Placement for Long-Segment superficial femoral artery lesions. Ann Vasc Surg 71:298–307
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V et al (2006) Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 13(6):701–710
Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Diamantopoulos A et al (2007) Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J Endovasc Ther 14(2):241–250
Mathlouthi A, Yei KS, Naazie I, Bertges DJ, Malas MB (2021) Increased mortality with paclitaxel-eluting stents is driven by lesion length. J Vasc Surg 73(2):548–53e2
Fong KY, Xin L, Ng J, Loh SEK, Ng JJ, Choong A (2022) A systematic review and meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial Disease. J Vasc Surg 77(4):1264–1273
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277(5698):665–667
Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A et al (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96(2):636–645
Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr. et al (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103(18):2289–2295
Gupta R, Al-Ali F, Thomas AJ, Horowitz MB, Barrow T, Vora NA et al (2006) Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 37(10):2562–2566
Feldman DN, Armstrong EJ, Aronow HD, Gigliotti OS, Jaff MR, Klein AJ et al (2018) SCAI consensus guidelines for device selection in femoral-popliteal arterial interventions. Catheter Cardiovasc Interv 92(1):124–140
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al (2016) Durable clinical effectiveness with paclitaxel-eluting stents in the Femoropopliteal artery: 5-Year results of the Zilver PTX Randomized Trial. Circulation 133(15):1472–1483
Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B et al (2015) Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv 8(1 Pt A):102–108
Schneider PA, Laird JR, Tepe G, Brodmann M, Zeller T, Scheinert D et al (2018) Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA Randomized Trial. Circ Cardiovasc Interv 11(1):e005891
Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB et al (2011) Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal Disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 4(5):495–504
Mills JL, Conte MS, Murad MH (2019) Critical review and evidence implications of paclitaxel drug-eluting balloons and stents in peripheral artery Disease. J Vasc Surg 70(1):3–7
Toutouzas K, Di Mario C, Falotico R, Takagi T, Stankovic G, Albiero R et al (2002) Sirolimus-eluting stents: a review of experimental and clinical findings. Z Kardiol 91 Suppl 3:49–57
Zhang Q, Lu L, Pu L, Zhang R, Shen J, Zhu Z et al (2007) Neointimal hyperplasia persists at six months after sirolimus-eluting stent implantation in diabetic porcine. Cardiovasc Diabetol 6:16
Skalsky I, Filova E, Szarszoi O, Parizek M, Lytvynets A, Maluskova J et al (2011) A periadventitial sirolimus-releasing mesh decreased intimal hyperplasia in a rabbit model. Physiol Res 60(3):585–588
Lammer J, Bosiers M, Zeller T, Schillinger M, Boone E, Zaugg MJ et al (2011) First clinical trial of Nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive Disease. J Vasc Surg 54(2):394–401
Oberhoff M, Herdeg C, Baumbach A, Karsch KR (2002) Stent-based antirestenotic coatings (sirolimus/paclitaxel). Catheter Cardiovasc Interv 55(3):404–408
Wessely R, Schomig A, Kastrati A (2006) Sirolimus and Paclitaxel on Polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 47(4):708–714
Im E, Hong MK (2015) Drug-eluting stents to prevent stent Thrombosis and restenosis. Expert Rev Cardiovasc Ther 14(1):87–104
Zhao HQ, Nikanorov A, Virmani R, Schwartz LB (2012) Inhibition of experimental neointimal hyperplasia and neoatherosclerosis by local, stent-mediated delivery of everolimus. J Vasc Surg 56(6):1680–1688
Wang X et al (2013) Oral everolimus inhibits intimal proliferation in injured carotid artery in rats. Chin Med J 126:1906–1912
Jensen LO, Thayssen P, Hansen HS, Christiansen EH, Tilsted HH, Krusell LR et al (2012) Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized trials with clinical outcome IV (SORT OUT IV). Circulation 125(10):1246–1255
Shiomi H, Kozuma K, Morimoto T, Igarashi K, Kadota K, Tanabe K et al (2014) Long-term clinical outcomes after everolimus- and sirolimus-eluting coronary stent implantation: final 3-year follow-up of the Randomized evaluation of Sirolimus-Eluting Versus Everolimus-Eluting Stent Trial. Circ Cardiovasc Interv 7(3):343–354
Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS et al (2015) Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and paclitaxel-eluting stents for coronary revascularization in Daily Practice: the COMPARE trial (a trial of Everolimus-Eluting stents and Paclitaxel stents for Coronary Revascularization in Daily Practice). JACC Cardiovasc Interv 8(9):1157–1165
Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F et al (2012) Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 125(23):2873–2891
Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R et al (2005) Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524(1–3):19–29
Levin AD, Vukmirovic N, Hwang C-W, Edelman ER (2004) Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A 101(25):9463–9467
Schwartz SM (1997) Smooth muscle migration in Atherosclerosis and restenosis. J Clin Invest 100(11 Suppl):S87–S89
Chen Y, Zeng Y, Zhu X, Miao L, Liang X, Duan J et al (2021) Significant difference between sirolimus and paclitaxel nanoparticles in anti-proliferation effect in normoxia and hypoxia: the basis of better selection of Atherosclerosis treatment. Bioact Mater 6(3):880–889
Farb A, Burke AP, Kolodgie FD, Virmani R (2003) Pathological mechanisms of fatal late coronary stent Thrombosis in humans. Circulation 108(14):1701–1706
Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al (2004) Localized hypersensitivity and late Coronary Thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109(6):701–705
Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol 47(1):175–181
Acknowledgements
Not applicable.
Funding
This study was supported by Changsha Natural Science Foundation (kq2007060) and Hunan province Natural Science Foundation (2023JJ60065).
Author information
Authors and Affiliations
Contributions
Conceptualization: KC. Data curation: KC. Formal analysis: KC. Funding acquisition: KC. Investigation: KC. Methodology: LX. Project administration: LX. Resources: LX. Software: LX. Supervision: XL. Validation: XL. Visualization: XL. Writing—original draft: KC, LX, XL. Writing—review & editing: KC, LX, XL.
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Chen, K., Xu, L. & Liu, X. Different drugs in drug-eluting stents for peripheral artery disease: a systematic evaluation and Bayesian meta-analysis. J Thromb Thrombolysis 57, 520–530 (2024). https://doi.org/10.1007/s11239-023-02932-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-023-02932-5